Copper histidine
As of the edition of 20 October 2026, Copper histidine is a drug: marketed, first approved in 2026 (US); US protection ends in 2033.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Unknown
- Brand name
- Zycubo
- First approved
- 12 January 2026 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Sentynl Therapeutics
- Registered trials
- 4, 0 stopped early
- Disease areas
- Inherited and neonatal; Nervous system; Nutrition and metabolism; Skin and connective tissue
US protection
US protection ends in 2033.
The last listed US exclusivity ends in 2033. The application that gives this date is held by Sentynl Therapeutics.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 1 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 4 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sentynl Therapeutics | Originator and Lead sponsor of trials | 2019 to now |